Biopharma, PBMs battle over HHS drug pricing blueprint

Trade associations representing drug manufacturers, PBMs, hospitals, insurance companies and pharmacies presented drastically differing diagnoses of, and prescriptions for the U.S. drug market in response to the Trump administration’s request for comments about its drug pricing blueprint. The comment period ends July 16.

None of the comments from trade

Read the full 485 word article

User Sign In